Hematological Manifestation in Lung, Breast and Git Malignencies

A Discriptive Study

  • Nilima Mahendrabhai Chaudhari
  • Shaila Shah
Keywords: Hematological manifestation, lung, GIT, breast malignancies


Background: Malignancy is one of the principle causes of death both in developed and developing countries. Methods: 102 lung, GIT and Breast malignancies patients were selected. The various hematological abnormalities in lung, GIT and breast malignancies were evaluated by estimation of hematological parameter. Complete hematological investigation was performed using Abbott cell-3700dyn hematology analyzer and peripheral smear using Field’s stain. Result: Hematological abnormalities were seen in Lung, GIT and Breast malignancies. The Anemia in 71(69.6%) cases of malignancies is most common hematological manifestation. The predominant peripheral smear finding was that of normocytic normochromic anemia (57.7%). The prevalence of leucocytosis and thrombocytosis were 33.3% and 36.2%. Conclusion: The present study showed a definite association of hematological manifestations viz anemia, leucocytosis   and   thrombocytosis with lung, GIT and breast malignancies.


1. Gupta A, Singh T and Gupta S. Hematological Manifestations In Non-Hematological Malignancies. International Journal of Bioassays 2015;4(10): 4376-4378
2. Kalyani P, Perimi R, Kameshwari SV, Assessment of severity of anemia and its effect on the quality of life (QUL) of patients suffering with various types of neoplasia. Biology and medicine 2009;1(3): 63- 72.
3. Caro JJ, Salas M, Ward A: Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 2001;91:2214-2221.
4. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002;94 (2):528-38
5. Cleeland CS, Demetri GD, Glaspy J, Cella D. Identifying Hemoglobin Level for Optimal Quality of Life: Results of an Incremental Analysis. American Society of Clinical Oncology, 35th Annual Meeting, Atlanta, [Abstract 2215]. 1999
6.Cazzola M, Mechanisms of anemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin. Medical Oncology, 2000;17(1):S11-S16.
7.Demetri GD, Ellen Thackery, Thomson Gale,. Anemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. British Journal of Cancer, 2001;84(1):31-37.
8. Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K. Tumor related leukocytosis is linked with poor prognosis in patient’s with lung carcinoma. 2001 ;92(9): 2399-405.
9. Dacie and Lewis. Practical Hematology, 10th edition. Churchill Livingstone Publication, 2006.
10. Varlotto J, Stevenson MA. Anemia, tumor hypoxemia and the cancer patient. Int J Radiat Oncol Biol Phys .2005;63(1): 25-36.
11.Schwartz RN. Anemia in patient’s with cancer: incidence, causes, impact, management and use of treatment guidelines and protocols. Am J Health Syst Pharm, 2007; quiz S28-30. 12. Knight K, Wade S, Balducci L. Prevalence and outcome of anemia in cancer: asystematic review of the literature. Am J Med,2004; 11 S-26 S.
13 Shoenfeld Y, Tal A, Berliner S, Pinkhas J. Leucocytosis in Non hematological Malignancies - A possible tumor associated marker. J cancer Res Clin Oncol. 1986 ;11:54-58
14.Granger JM, Kontoyiannis DP. Etiology and outcome of extreme leucocytosis in 758 non hematologic cancer patients: a retrospective single institution study. Cancer 2009;115(17): 3919-23.
15.Pederson LM, Milman N. Diagnostic significance of platelet count and other blood analysis in patients with lung cancer. 2003;10(1):213-6.
Original Article